Dyadic announces top-line results from its successful phase 1 clinical trial for a first-in-human filamentous fungal-based vaccine candidate

Primary endpoint met demonstrated safety and reactogenicity of dyai-100 recombinant protein c1-cell produced antigen was both safe and well-tolerated no serious adverse events reported final clinical study report available in the coming weeks jupiter, fla., nov. 29, 2023 (globe newswire) -- dyadic international, inc. ("dyadic", "we", "us", "our", or the "company") (nasdaq: dyai), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced successful top-line results for the phase 1 clinical trial of its recombinant protein rbd vaccine candidate, dyai-100.
DYAI Ratings Summary
DYAI Quant Ranking